These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 17555457)

  • 1. Use of recombinant factor VIIa (rFVIIa) in the management of intractable haemorrhage: a survey of current UK practice.
    Biss TT; Hanley JP
    Br J Haematol; 2007 Jul; 138(1):126-8. PubMed ID: 17555457
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant activated factor VIIa (rFVIIa) in intractable haemorrhage: use of a clinical scoring system.
    Pugh R; Wenstone R; Goh N
    Vox Sang; 2006 May; 90(4):331; author reply 332. PubMed ID: 16635077
    [No Abstract]   [Full Text] [Related]  

  • 3. Antidotes to haemorrhage: recombinant factor VIIa.
    Kessler CM
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):183-97. PubMed ID: 15171966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential use of recombinant activated factor VII in trauma and surgery.
    Sapsford W
    Scand J Surg; 2004; 93(1):17-23. PubMed ID: 15116814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage.
    Bowles KM; Callaghan CJ; Taylor AL; Harris RJ; Pettigrew GJ; Baglin TP; Park GR
    Br J Anaesth; 2006 Oct; 97(4):476-81. PubMed ID: 16914465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful use of recombinant factor VIIa in pelvic fracture haemorrhage.
    Dhruva KK; Joel VD; Antony S; Vinodan K
    J Indian Med Assoc; 2006 Jan; 104(1):42, 44. PubMed ID: 16850866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
    Astermark J; Rocino A; Von Depka M; Van Den Berg HM; Gringeri A; Mantovani LG; Morado M; Garrido RP; Schiavoni M; Villar A; Windyga J;
    Haemophilia; 2007 Jan; 13(1):38-45. PubMed ID: 17212723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
    Mayo A; Misgav M; Kluger Y; Geenberg R; Pauzner D; Klausner J; Ben-Tal O
    Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant factor VIIa in the treatment of bleeding.
    Midathada MV; Mehta P; Waner M; Fink LM
    Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis and results of the recombinant factor VIIa extended-use registry.
    Laffan M; O'Connell NM; Perry DJ; Hodgson AJ; O'Shaughnessy D; Smith OP
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S35-8. PubMed ID: 14567534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant factor VIIa used to control massive haemorrhage during renal transplantation surgery; vascular graft remained patent.
    Dunkley SM; Mackie F
    Hematology; 2003 Aug; 8(4):263-4. PubMed ID: 12911945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A response to 'the use of recombinant activated factor VII in the control of haemorrhage following blunt pelvic trauma.
    Geoghegan J; Tasker L
    Anaesthesia; 2005 Nov; 60(11):1156-7; author reply 1157. PubMed ID: 16229713
    [No Abstract]   [Full Text] [Related]  

  • 13. [Administration of activated recombinant factor VII (novo seven) for the control of massive bleeding in gynecology].
    Tanchev S; Pandurski F; Georgiev A; Gesheva Iu; Platikanov V; Dinov P
    Akush Ginekol (Sofiia); 2004; 43 Suppl 2():32-5. PubMed ID: 15518274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Last-ditch' use of recombinant factor VIIa in patients with massive haemorrhage is ineffective.
    Clark AD; Gordon WC; Walker ID; Tait RC
    Vox Sang; 2004 Feb; 86(2):120-4. PubMed ID: 15023181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B; Wiis J
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?
    Poon MC
    Curr Hematol Rep; 2003 Mar; 2(2):139-47. PubMed ID: 12901145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of recombinant activated factor VII in the control of haemorrhage following blunt pelvic trauma.
    Udy A; Vaghela M; Lawton G; Sigston P
    Anaesthesia; 2005 Jun; 60(6):613-6. PubMed ID: 15918835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant factor VIIa in the treatment of intractable bleeding in vascular surgery.
    Manning BJ; Hynes N; Courtney DF; Sultan S
    Eur J Vasc Endovasc Surg; 2005 Nov; 30(5):525-7. PubMed ID: 16099693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of recombinant factor VIIa for bleeding in paediatric practice.
    Millar CG; Stringer MD; Sugarman I; Richards M
    Haemophilia; 2005 Mar; 11(2):171-4. PubMed ID: 15810920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia.
    Baudo F; de Cataldo F; Gaidano G;
    Haematologica; 2004 Jun; 89(6):759-61. PubMed ID: 15194550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.